Summary
To prospectively evaluate the prevalence of hepatitis B virus (HBV) positivity and study the evolution of HBV profile during cancer chemotherapy, serum HBV markers and liver biochemistry were determined in 1008 of 1402 (72%) cancer patients admitted in our Unit and in all 920 (91%) who received chemotherapy. We found that 54 (5.3%) were HBsAg carriers while 443 (44%) had at least one HBV marker positive. Of the latter, 405 (91%) were HBcAb+ve, 321 (72%) HBsAb+ve and 212 (48%) HBeAb+ve. No patient was HBeAg+ve. Among 920 chemotherapy receivers, 374 (41%) were HBcAb+ve, 280 (30%) HBsAb+ve and 178 (19%) HBeAb+ve. Fifty (5.4%) were HBsAg carriers (versus 0.6% in Greek blood donors). All 50 were systematically screened for HBsAg and HBsAb status throughout chemotherapy, during follow-up or until their death, and liver biochemistry was performed before each chemotherapy course. Stable antigenaemia was observed in 43/50 (86%) while 7/50 (14%) developed clinical and/or biochemical hepatitis. Six of these seven developed serum anti-HBs antibodies with an associated decrease of serum HBsAg titres. We conclude that reactivation of HBV infection during chemotherapy is not rare (14%), while disappearance of HBs antigenaemia is neither a frequent nor usually a permanent phenomenon.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alexopoulos, CG, Vaslamatzis, M, Zoublios, C & Chatzidimitriou, G (1992). Reactivation of hepatitis B in HBsAg carriers during cancer chemotherapy. Ann Oncol 3: 65
Alexopoulos, CG, Vaslamatzis, M & Chatzidimitriou, G (1997). Incidence of hepatitis B virus (HBV) positivity and behaviour of hepatitis B surface antigen (HBsAg) carrier state in cancer patients, during chemotherapy (CT). Proc Am Soc Clin Oncol 16: A1490
Bird, GLA, Smith, H, Portmann, B, Alexander, GJM & Williams, R (1989). Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Quart J Med, New Series 73 270: 895–902.
Gallbraith, RM, Eddleston, AL, Williams, R, Zucherman, AJ & Bagshaw, KD (1975). Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2: 528–530.
Hoofnagle, JH, Dusheiko, GM, Schafer, DF, Jones, EA, Micetich, CK, Young, CR & Costa, J (1982). Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Am Intern Med 96: 447–449.
Lau, JYN, Lai, CL, Lin, HJ, Lok, ASF, Liang, RHS, Wu, CP, Chan, KT & Todd, D (1989). Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart J Med New Series 73 270: 911–917.
Nakamura, Y, Motokura, T, Fujita, A, Yamashita, T & Ogata, E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan 1987–1991. Cancer 78: 2210–2215.
Ngan, R, Tung, S, Lau, WH & Lam, J (1995). Long term results of aggressive lymphoma using PROMACE-CYTABOM, peculiar patient group and toxicity. Proc Am Soc Clin Oncol 14: 1251
Ohtsu, T, Sai, T, Oka, M, Shgai, Y & Tobinai, K (1991). Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 21: 360–365.
Pinto, CP, Hu, E, Bernstein-Singer, M & Pinter-Brown, L Govindarajans (1990). Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65: 878–884.
Scullard, GH, Smith, CI, Merigan, TC, Robinson, WS & Gregory, PB (1981). Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987–991.
Wands, JR, Chura, CM, Roll, FJ & Maddrey, WC (1975). Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105–112.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Alexopoulos, C., Vaslamatzis, M. & Hatzidimitriou, G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81, 69–74 (1999). https://doi.org/10.1038/sj.bjc.6690652
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690652
Keywords
This article is cited by
-
Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors
BMC Cancer (2015)
-
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
BMC Gastroenterology (2014)
-
Traitement préemptif de la réactivation de l’hépatite virale B des patients sous chimiothérapie anticancéreuse
Journal Africain du Cancer / African Journal of Cancer (2014)
-
Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management
Hepatology International (2013)
-
Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer
Nature Reviews Clinical Oncology (2012)